MRK: Merck & Co., Inc. Company Profile & Statistics

About

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Info & Links

CEO

Robert M. Davis

Headquarters

126 East Lincoln Avenue
Rahway, NJ 07065, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

85,700

Employees

75,000

Merck & Co., Inc. Statistics

Valuation Measures

Market Capitalization²

205.84B

Enterprise Value

232.06B

Enterprise Value/EBITDA(ttm)

9.28

Price to Earnings Ratio(ttm)

11.48

Price to Sales(ttm)

3.46

Price to Book(mrq)

4.98

Price to Cash(ytd)

28.82

Profitability

Gross Margin(ttm)

76.44%

Operating Margin(ttm)

30.30%

Profit Margin(ttm)

27.37%

Return on Equity(ttm)

45.35%

Return on Invested Capital(ttm)

21.78%

Return on Assets(ttm)

17.36%

Income Statement

Revenue(ttm)

63.92B

Revenue Per Share(ttm)

25.46

Gross Profit(ttm)

48.85B

EBITDA(ttm)³

25.01B

Net Income Available to Common(ttm)

17.43B

Diluted EPS(ttm)

6.73

Share Statistics

Beta (5Y Monthly)

0.38

52-Week Change

-36.90%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

2.51B

Dividend Yield

3.70%

Float⁴

2.53B

% Held by Insiders

0.09%

% Held by Institutions

76.07%

Balance Sheet

Total Cash(mrq)

9.23B

Total Cash Per Share(mrq)

3.67

Total Debt(mrq)

34.84B

Total Debt/Equity(mrq)

71.99%

Current Ratio(mrq)

1.41%

Quick Ratio(mrq)

1.15%

Book Value Per Share(mrq)

19.24

Cash Flow

Operating Cash Flow Per Share(ytd)

0.99

Free Cash Flow(ytd)

1.17B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MRK

Merck & Co., Inc.

Merck & Co., Inc. Profile